{"entity":{"id":"lns8801","kind":"drug","name":"LNS8801","aka":[],"tldr":"LNS8801 is an experimental investigational agent whose form is not stated in the registry from Linnaeus Therapeutics in phase 3 trials for melanoma, aimed at Estrogen receptor (ERα).","summary":"LNS8801 is an investigational agent whose form is not stated in the registry developed by Linnaeus Therapeutics. Its target is Estrogen receptor (ERα). ClinicalTrials.gov describes the intervention as: G protein-coupled estrogen receptor (GPER) agonist. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06624644 (A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma), in melanoma. The largest, NCT06624644, plans to enrol 135 participants with primary completion expected 2029-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of LNS8801","url":"https://clinicaltrials.gov/search?intr=LNS8801"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["estrogen-receptor"],"drugs":[],"companies":["linnaeus-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06624644","nct04130516"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","mechanism":"Investigational agent whose form is not stated in the registry directed at Estrogen receptor (ERα), as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lns8801/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"company":[{"id":"linnaeus-therapeutics","kind":"company","name":"Linnaeus Therapeutics","route":"/companies/linnaeus-therapeutics/"}],"trial":[{"id":"nct06624644","kind":"trial","name":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","route":"/trials/nct06624644/"},{"id":"nct04130516","kind":"trial","name":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","route":"/trials/nct04130516/"}]}}